Gilead Sciences Inc (GILD)

GILD (NASDAQ:Drugs) EQUITY
$75.15
pos +1.40
+1.90%
Today's Range: 73.62 - 74.27 | GILD Avg Daily Volume: 8,604,800
Last Update: 07/26/17 - 4:35 PM EDT
Volume: 10,002,450
YTD Performance: 2.97%
Open: $74.10
Previous Close: $73.74
52 Week Range: $77.92 - $120.37
Oustanding Shares: 1,306,728,398
Market Cap: 97,207,525,527
6-Month Chart
TheStreet Ratings Grade for GILD
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 7 9 9 10
Moderate Buy 1 1 1 1
Hold 9 8 9 9
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.12 1.94 2.00 1.95
Latest Dividend: 0.52
Latest Dividend Yield: 2.80%
Dividend Ex-Date: 06/14/17
Price Earnings Ratio: 7.86
Price Earnings Comparisons:
GILD Sector Avg. S&P 500
7.86 7.90 31.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
9.86% -16.73% -17.92%
GROWTH 12 Mo 3 Yr CAGR
Revenue -6.90 1.70 0.39
Net Income -25.50 3.40 0.63
EPS -16.50 4.00 0.70
Earnings for GILD:
EBITDA 18.79B
Revenue 30.39B
Average Earnings Estimates
Qtr (06/17) Qtr (09/17) FY (12/17) FY (12/18)
Average Estimate $2.11 $2.00 $7.98 $7.18
Number of Analysts 5 5 7 3
High Estimate $2.29 $2.15 $8.72 $7.59
Low Estimate $1.87 $1.88 $6.86 $6.46
Prior Year $3.03 $2.70 $11.37 $7.98
Growth Rate (Year over Year) -30.23% -25.78% -29.78% -10.07%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
RMPIA

updateRedburn Initiates Gilead with Buy Rating

Jul 26, 2017 | 9:10 AM EDT

Gilead Sciences stock coverage was initiated at Redburn with a "Buy" rating. 

RMPIA
By

Bret Jensen

 | Jul 23, 2017 | 2:00 PM EDT
But this needs to heat up again for the sector to rally in a big way.
RMPIA
By

Bret Jensen

 | Jul 21, 2017 | 1:00 PM EDT
However, it will take acquisition activity to heat up again for the sector to rally in a big way.
RMPIA
By

Bret Jensen

 | Jul 7, 2017 | 1:30 PM EDT
The two giants likely won't be home runs, but they remain stalwarts in the biotech space.
RMPIA
By

Bret Jensen

 | Jul 7, 2017 | 11:30 AM EDT
The two giants likely won't be home runs, but they remain stalwarts in the biotech space.
RMPIA
By

Guy Ortmann

 | Jun 26, 2017 | 12:16 PM EDT
Bullish and bearish reversals for this week.
RMPIA
By

Bret Jensen

 | Jun 23, 2017 | 11:30 AM EDT
There are reasons to believe rallies in BioDelivery Sciences and Flexion Therapeutics should continue.
RMPIA
By

Doug Kass

 | Jun 22, 2017 | 7:12 AM EDT
"For a day where the S&P was essentially flat, there was a lot going on beneath the surface.
RMPIA
By

Jim Cramer

 | Jun 19, 2017 | 2:30 PM EDT
Banks, tech and healthcare are all seeing renewed buying.
RMPIA
By

Doug Kass

 | Jun 12, 2017 | 4:37 PM EDT
  Top 10 Reasons the Lambs May Be Sheared ... or Slaughtered.    Stated simply, I see a trend change. &nbs …
we'll take this nice winner off the table SOLD ADSK AUG 105 CALL AT 9 (in at 4.45...
Costco (COST) is beginning to firm up near the $150.00 area. The stock bottomed here at l...
We like this move today on good turnover and strong option flow. BOUGHT FCX OCT 15 CALL...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.